Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALBOLA
2024-516466-11-00Phase 2Authorised
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in pancreatic adenocarcinoma (PDAC), sponsored by Azienda Ospedaliera Universitaria Policlinico. Primary endpoint: Objective response rate (ORR). Planned start Nov 2024; status: authorised.
02
Drugs
olaparib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-516466-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516466-11-00.